Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation
Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen
Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen
View: Text | PDF
Research Article Cardiology Immunology

Proteomic profiling of plasma extracellular vesicles reveals a therapeutically targetable liver-heart axis in cardiac transplantation

  • Text
  • PDF
Abstract

Extracellular vesicle–mediated interorgan communication represents a promising frontier in transplant immunology; however, its role in cardiac allograft rejection remains poorly characterized. We performed proteomic profiling of plasma-derived extracellular vesicles in a rat heterotopic heart transplantation model and identified a distinct liver-predominant protein signature during acute rejection, with antithrombin III (ATIII) emerging as a top candidate. Functional validation revealed that pharmacological extracellular vesicle inhibition intensified systemic and intragraft inflammation, whereas adeno-associated virus–mediated silencing of hepatic ATIII directly accelerated allograft rejection. Conversely, adeno-associated virus–mediated hepatocyte-specific ATIII overexpression attenuated rejection pathology, reduced immune cell recruitment, and markedly prolonged median graft survival. This protective effect was achieved without evidence of coagulopathic complications, indicating an immunomodulatory mechanism beyond ATIII’s canonical anticoagulant function. Mechanistically, ATIII overexpression was associated with upregulation of heme oxygenase-1 (HO-1) in the liver and suppression of proinflammatory cytokine expression in the graft. These findings highlight hepatocyte-derived extracellular vesicles as important mediators of a liver-heart signaling axis in transplant rejection and further implicate the protein ATIII as a contributor to this axis. Our study reveals a therapeutically targetable liver-heart signaling axis in transplant rejection, whereby enhancing liver-derived ATIII or its downstream pathways (such as HO-1) could attenuate acute cardiac allograft rejection.

Authors

Shiyu Dai, Wei Zhou, Fangyu Chen, Huanyu Zhang, Zhenchun Ji, Xuejing Zong, Wanruo Zhang, Jie Hu, Shumin Jiang, Fei Wang, Zhenya Shen

×

Figure 7

Liver-targeted ATIII overexpression attenuates cardiac allograft rejection.

Options: View larger image (or click on image) Download as PowerPoint
Liver-targeted ATIII overexpression attenuates cardiac allograft rejecti...
(A) Experimental workflow. Lewis rats were i.v. injected with AAV-Serpinc1 or AAV-GFP (control) for hepatocyte-specific overexpression prior to Brown Norway heart transplantation. For survival analysis, graft failure was determined by the loss of palpable cardiac contractions. For mechanistic studies, heart allografts, liver, and plasma were harvested at postoperative day 5. (B) Kaplan-Meier curves comparing allograft survival between groups. Log-rank test (AAV-GFP, n = 8; AAV-Serpinc1, n = 6). (C and D) Hepatic ATIII verification. Representative Western blots (C) and quantitative analysis (D) of ATIII expression in recipient livers. Blots are representative of 2 independent experiments. (E) Representative H&E, CD4, CD8, and CD68 IHC staining of cardiac allografts from the biological replicates. Scale bar: 50 μm. (F) International Society for Heart and Lung Transplantation (ISHLT) grading based on allograft histology. (G) Graft inflammatory profile. Relative mRNA levels of proinflammatory cytokines (Il1b, Tnfa, Il6, Ifng), chemokines (Cxcl9, Cxcl10), cytotoxic molecules (Prf1, Gzmb), and regulatory factors (Tgfb1, Il10) in cardiac allografts from control and hepatocyte-specific ATIII-overexpressing recipients. (H and I) Systemic immune monitoring. Peripheral WBC counts (H) and lymphocyte counts (I) in recipient rats. Data are presented as individual values with median for F, and as mean ± SEM for other bar graphs (D and G–I). Sample sizes for C–I: AAV-GFP, n = 4; AAV-Serpinc1, n = 5 biological replicates. Statistical significance was determined by Mann-Whitney U test for F, 2-tailed Welch’s t test for Il1b in G and H, unpaired 2-tailed Student’s t test for all other comparisons in D, G, and I. *P < 0.05, **P < 0.01, ns, not significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts